M.B.A., finance, MIT Sloan School of Management; Ph.D., political science, MIT; B.A., University of California, San Diego
Summary of Experience
Dr. Rosberg specializes in directing complex, data-driven analysis on projects requiring the application of financial and economic theory to address issues in both litigation and strategic contexts. He has substantial experience in securities, antitrust, and corporate governance litigation, particularly as it relates to Foreign Corrupt Practices Act (FCPA) cases. His recent case work has involved supporting leading experts in several major securities cases, ranging from investment suitability matters to disputes surrounding mortgage-backed securities, as well as consulting on a number of high-profile antitrust cases. Dr. Rosberg has specific expertise in conducting cost accounting analysis for antitrust litigation and investigations, in which he analyzes companies' variable costs and the use of managerial accounting data in pass-through analyses. He has also collaborated with experts in a wide variety of corporate governance cases, including matters involving the appropriateness and impact of board decisions, whether boards have followed acceptable processes in their decision making, and whether corporate officers acted reasonably in specific circumstances. In addition, he has supported experts preparing testimony on the question of whether certain state owned enterprises constituted government instrumentalities as defined under the FCPA. Prior to joining Analysis Group, Dr. Rosberg was a consultant at The Parthenon Group and taught at Dartmouth and Boston College.
Analysis of Cost Behavior When Calculating Damages Part 1: Understanding Costs; Analysis of Cost Behavior When Calculating Damages Part 2: Analyzing Avoided Costs
Business Law Today, ABA Business Law Section, November 15, 2018
Today's General Counsel, February/March 2013
Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia
J Natl Compr Canc Netw 2005 Nov;3(6):807-16
Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis
Clin Drug Investig. 2005;25(1):33-48.